Myriad Genetics acquires maker of blood test and rheumatoid arthritis app for $270 million
Thu, 06 Feb 2014 15:57:31 GMT
Molecular diagnostic company Myriad Genetics has acquired Crescendo Biosciences for $270 million, in cash, which included repayment of a $25 million loan that Myriad made to Crescendo in 2011. Investor Safeguard Scientifics has invested $11 million Crescendo Biosciences, giving it a 13 percent stake, and expect to earn $40 million as part of the deal. Following the acquisition, [...]
Thermo Fisher completes $13.6bn Life Tech acquisition
Wed, 05 Feb 2014 06:30:00 GMT
Thermo Fisher Scientific has completed its acquisition of Life Technologies, a life sciences company, for approximately $13.6bn and the assumption of $1.5bn in net debt.
Week in Review: Mindray Acquires Control of US-China IVD Company
Sun, 02 Feb 2014 08:59:01 GMT
Mindray Medical acquired a controlling stake in Shanghai Long Island Biotec, which makes thrombotic and hemostatic reagent products; Actavis continued its exit from China by selling its interest in a China JV to Zhejiang Chiral Medicine Chemicals; Biogen Idec out-licensed China rights for an eight-drug portfolio, including its flagship MS drugs, to UCB (Euronext: UCB) of Belgium; Wanbang Biopharma in-licensed China rights to a Sirona Biochem pre-clinical diabetes treatment, paying up to $9.5 million; AstraZeneca and the Shanghai Institutes of Biological Sciences agreed to collaborate on a basic research project in cardiovascular disease; Sinovac Biotech filed an application with the CFDA to begin clinical trials of its avian flu A(H7N9) vaccine; and BioTime of California began a concurrent study of its bladder cancer diagnostic test in the US and China. More details….
Stock Symbols: (NYSE: MR) (NYSE: ACT) (NSDQ: BIIB) (TSX: SBM; OTCQS: SRBCF) (NYSE: AZN) (NSDQ: SVA) (NYSE: BTX) Share this with colleagues:
Thermo Fisher Sells Assets to GE Healthcare for $1.1B
Fri, 10 Jan 2014 07:00:00 GMT
Thermo Fisher Scientific is selling three business lines to GE in a $1.1 billion deal intended to expedite European Commission approval for its $13.6 billion acquisition of Life Technologies.
BioClinica and CCBR-Synarc to merge with Water Street, JLL and Ampersand sharing ownership
Thu, 16 Jan 2014 12:30:35 GMT
BioClinica and CCBR-Synarc have agreed to merge with Water Street, JLL and Ampersand sharing ownership.
Carlyle Group makes binding offer to acquire J&J’s Ortho-Clinical Diagnostics
Fri, 17 Jan 2014 11:34:37 GMT
Johnson & Johnson has received a binding offer from the Carlyle Group to acquire its Ortho-Clinical Diagnostics business for $4.15 billion. Ortho-Clinical Diagnostics delivers in vitro diagnostic products that give healthcare professionals around the world the knowledge they need to make better treatment decisions sooner.
Carlyle Group to buy Johnson & Johnson's diagnostic unit for $4.15bn
Fri, 17 Jan 2014 06:30:00 GMT
The Carlyle Group has agreed to buy Johnson & Johnson's Ortho-Clinical Diagnostics (OCD) business for $4.15bn.
BioClinica, CCBR-SYNARC To Merge
Sat, 18 Jan 2014 08:58:08 GMT
BioClinica and CCBR-SYNARC have signed an agreement to merge their companies
BioMerieux Finalizes BioFire Diagnostics Acquisition
Thu, 16 Jan 2014 20:09:04 GMT
CytoCore, Inc. To Acquire
Mon, 13 Jan 2014 00:00:00 GMT